TP53 and cancer: Results revealed that cancer patients harboring mutant (MUT) TP53 had a higher risk of developing metastases to lymph nodes (Fig. 1A, lymph node-negative (N0) vs lymph node-positive (N1+)) and distant organs (Fig. 1B) as compared to those having WT TP53. In addition, median overall survival was over 1.7-fold longer in patients with WT TP53 than in those with MUT TP53 (Fig. 1C).